Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCTHO0373

Title

Identification and Validation of Molecular Markers in Lung Cancer (SPORE)

Principal Investigator(s)

Pierre Massion

Details

  • Protocol No. VICCTHO0373
  • Open Date: 05/03/2001
  • Staging: Pilot
  • Age Group: Adults
  • Scope: Local
  • Objective:
  • Disease Sites: Lung
  • Therapies: None Specified
  • Drugs: None Specified
  • Participating Institutions: Veterans Administration; Vanderbilt University; St. Thomas Health Services
  • National Clinical Trial ID: NCT00899028
  • Secondary Protocol No: VICCTHO0373

Description

None Provided.

Eligibility

Ages Eligible for Study:18 Years and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:Accepts Healthy Volunteers

Criteria

DISEASE CHARACTERISTICS:
• Meets 1 of the following criteria:
• Known or previously diagnosed lung cancer
• Suspected lung cancer, including the following:
• Completely resected stage I lung cancer (with no evidence of metastatic disease) for which patient is at risk for developing secondary disease
• Suspected of having lung cancer due to clinical symptoms, such as positive sputum cytology, hemoptysis, unresolved pneumonia, persistent cough, and positive x-ray
• Healthy volunteer
PATIENT CHARACTERISTICS:
• WBC ≥ 2,000/mm³ but ≤ 20,000/mm³
• Platelet count ≥ 50,000/mm³
• Not pregnant
• No uncontrolled hypertension (i.e., systolic blood pressure > 200 mm Hg, diastolic blood pressure > 120 mm Hg)
• No unstable angina
• No known bleeding disorder
• No other contraindications for white light bronchoscopic examination
• No other contraindications for fluorescence examination
PRIOR CONCURRENT THERAPY:
• More than 3 months since prior fluorescent photosensitizing agents (hematoporphyrin derivatives)
• More than 3 months since prior and no concurrent chemopreventative drugs (e.g., tretinoin)
• More than 6 months since prior ionizing radiation treatment to the chest
• More than 6 months since prior systemic cytotoxic chemotherapy
• No concurrent anticoagulant therapy